13F Holdings
中文EN

OCEA Ocean Biomedical, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1869974 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY1.6%
TTM EPS YoY6.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,276.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5,940.6%
Debt / equity—
Current ratio0.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-1,097.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue———
R&D expense$26,000$709,000$8.41M
SG&A expense$3.77M$9.51M$7.71M
Operating income-$3.80M-$10.21M-$16.12M
Interest expense—$50,000$691
Net income-$9.48M-$114.47M-$17.36M
EPS (basic)-0.34-4.35-0.74
EPS (diluted)-0.34-4.35-0.74
Weighted avg. shares (diluted)27.50M26.29M23.36M
Banking
Net interest income-$2.05M-$1.76M-$1.24M
Balance sheet
Cash & equivalents$200,000$4,000$34,000
Current assets$812,000$2.11M$1.84M
Total assets$902,000$5.50M$1.84M
Current liabilities$33.89M$30.01M$12.66M
Short-term debt—$3.20M$776,000
Total liabilities$98.52M$96.26M$12.66M
Shareholders' equity-$97.62M-$90.76M-$10.82M
Shares outstanding34.87M34.65M23.36M
Cash flow statement
Operating cash flow-$4.18M-$9.43M-$993,000
Investing cash flow——-$2.10M
Financing cash flow$3.40M$10.40M$967,000
Stock-based compensation$745,000$1.21M$12.38M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.